Skip to main content

Table 1 Characteristics of study population

From: Genetic polymorphism of the OPG gene associated with breast cancer

Clinical parameters

Breast cancer patients (n=307)

Healthy controls (n=396)

Age (median) in years k

56 (22-91)

45 (18-88)

Menopausal status

n=287

 

Premenopausal

88 (31%)

 

Postmenopausal

179 (62%)

 

Perimenopausal

20 (7%)

 

Unknown

20

 

Tumor growth

n=303

 

Invasive

275 (91%)

 

Non-invasive

28 (9%)

 

Unknown

4

 

Localization

n=306

 

Right

123 (40%)

 

Left

173 (57%)

 

Bilateral

10 (3%)

 

Unknown

1

 

Type a, b

n=255

 

Ductal

189 (74%)

 

Lobular

34 (13%)

 

Other types

32 (13%)

 

Unknown

21

 

Tumor size (T) a, b, c

n=229

 

T1 (< 2 cm)

142 (62%)

 

T2 (>/= 2 cm – 5 cm)

76 (33%)

 

T3 (</= 5 cm)

6 (3%)

 

T4 (infiltration of the chest

5 (2%)

 

wall/skin)

  

Unknown

24

 

Nodal status (N) b, c

n=250

 

N+

75 (30%)

 

N-

175 (70%)

 

Unknown

36

 

Distant metastases (M)

n=292

 

M+

16 (5%)

 

osseous

10 (3%)

 

M-

276 (95%)

 

Unknown

15

 

Tumor grading (G)

n=245

 

G1

16 (6%)

 

G2

161 (63%)

 

G3

78 (31%)

 

Unknown

49

 

Estrogen receptor (ER) d

n=275

 

ER+

224 (81%)

 

ER-

51 (19%)

 

Unknown

32

 

Progesterone receptor (PR) b, d

n=274

 

PR+

193 (70%)

 

PR-

81 (30%)

 

Unknown

32

 

Her-2 a, b, e

n=208

 

Her2+

42 (20%)

 

Her2-

166 (80%)

 

Unknown

67

 

Ki67 a, b, f

n=187

 

Ki67+

84 (45%)

 

Ki67-

103 (55%)

 

Unknown

88

 

CEA f

n=107

 

CEA+

26 (24%)

 

CEA-

81 (76%)

 

Unknown

200

 

CA15-3 h

n=215

 

CA15-3+

81 (38%)

 

CA15-3-

134 (62%)

 

Unknown

92

 

Body mass index (BMI) m

n=219

 

BMI < 28

150 (68%)

 

BMI >/= 28

69 (32%)

 

Unknown

88

 

Subgroup a, i

n=249

 

Triple negative

22 (9%)

 

Non triple negative

227 (91%)

 

Unknown

30

 

Subgroup a, j

n=262

 

Risk group

18 (7%)

 

Non risk group

244 (93%)

 

Unknown

15

 
  1. aOnly invasive tumors are included; bBilateral tumors are only included if both sides had the same result; cExclusion of cases with neoadjuvant chemotherapy; dImmunoreactive score: 0: negative, 1-12: positive; eHer2 = human epidermal growth factor receptor 2; immunoreactive score 0-2 (FISH negative): negative, 2 (FISH positive)-3: positive; fKi67 = marker for proliferation (< 13%: negative, >/= 13%: positive); gCEA = carcinoembryonic antigen (tumor marker, < 3 ng/ml: negative, >/= 3 ng/ml: positive); hCA15-3 = tumor marker (< 21 U/ml: negative, >/= 21 U/ml: positive); iTriple negative = ER, PR and Her2 negative; jRisk group: T >/= 2, G3, ER negative; FISH = fluorescence in situ hybridization; ksignificant difference (p< 0.001), age-adjusted statistical analysis performed; mBMI >/= 28 was defined as overweight in order to age-adjustment [https://www.uni-hohenheim.de/wwwin140/info/interaktives/bmi.htm].
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us